ALLMedicine™ Vaginal Cancer Center
Research & Reviews 172 results
https://clinicaltrials.gov/ct2/show/NCT02466971
Jun 22nd, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase overall survival relative to the standard/control regimen of cisplatin and radiation in women with uterine cervix or...
https://clinicaltrials.gov/ct2/show/NCT02595879
Jun 8th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy. II. To determine the oral bioavailability of triapine. III. ...
https://clinicaltrials.gov/ct2/show/NCT04892043
Jun 3rd, 2022 - This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients ...
https://doi.org/10.3390/curroncol29050250
Current Oncology (Toronto, Ont.); Kulkarni A, Dogra N et. al.
May 28th, 2022 - Primary vaginal cancer is a rare gynecologic malignancy. Given the rarity of the disease, standardized approaches to management are limited, and a great variety of therapeutic conditions are endorsed. This paper reviews advances in surgical approa...
https://clinicaltrials.gov/ct2/show/NCT04084951
May 16th, 2022 - This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune checkpoint inhibitors...
Guidelines 2 results
https://doi.org/10.1016/j.jacr.2021.08.011
Journal of the American College of Radiology : JACR; , Kilcoyne A et. al.
Nov 20th, 2021 - Primary vaginal cancer is rare, comprising 1% to 2% of gynecologic malignancies and 20% of all malignancies involving the vagina. More frequently, the vagina is involved secondarily by direct invasion from malignancies originating in adjacent orga...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882649
International Journal of Clinical Oncology; Saito T, Tabata T et. al.
Nov 22nd, 2017 - Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines...
Clinicaltrials.gov 18 results
https://clinicaltrials.gov/ct2/show/NCT02466971
Jun 22nd, 2022 - PRIMARY OBJECTIVE: I. To evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase overall survival relative to the standard/control regimen of cisplatin and radiation in women with uterine cervix or...
https://clinicaltrials.gov/ct2/show/NCT02595879
Jun 8th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy. II. To determine the oral bioavailability of triapine. III. ...
https://clinicaltrials.gov/ct2/show/NCT04892043
Jun 3rd, 2022 - This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients ...
https://clinicaltrials.gov/ct2/show/NCT04084951
May 16th, 2022 - This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune checkpoint inhibitors...
https://clinicaltrials.gov/ct2/show/NCT03956498
Mar 24th, 2022 - Prospective, monocentric study evaluating the impact of a nurse-led sexological follow-up on sexual function in patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy. The study procedure will consist of nurse-led sexolog...
News 28 results
https://www.onclive.com/view/ahn-cancer-institute-recruits-top-physician-researchers-from-upmc-for-high-level-roles
Dec 22nd, 2021 - Allegheny Health Network (AHN) today announced the recruitment of two nationally recognized physician-researchers in radiation oncology, medical oncology and molecular genetics from the University of Pittsburgh Medical Center to assume high level ...
https://www.onclive.com/view/recruitment-to-phase-2-trial-examining-pds0101-triplet-in-hpv-cancers-temporarily-suspended
Oct 29th, 2021 - The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute (NCI)–led phase 2 trial (NCT04287868), which is evaluating a novel triplet combination co...
https://www.onclive.com/view/7-in-2011-a-short-list-of-drugs-to-watch
Dec 5th, 2020 - From tiny biotech firms to giant pharmaceutical companies, the oncology drug development pipeline is pulsing with activity. There are nearly 900 potential new medicines and vaccines to treat cancer under study in the United States, according to th...
https://www.onclive.com/view/clinical_abstracts_grljun2008
Dec 5th, 2020 - Click here to view as PDF. â–º India Different HIV-Associated Cancers in India In the United States, one of the most common cancers in patients with human immunodeficiency virus infection (HIV) is Kaposi’s sarcoma. However, a new study finds th...
https://www.onclive.com/view/winter-2010-fda-updates
Dec 5th, 2020 - Voting 10-0, an Oncologic Drugs Advisory Committee recommended that the FDA approve AstraZeneca’s novel drug Zactima (vandetanib) for patients with medullary thyroid cancer, which is a rare form of the disease. Noting concerns about the drug’s po...
